Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Targeting specific enzyme reverses radiation-induced immune suppression in cancer (opens in a new tab)

news-medical.net · 2026-10-30

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredIn blood samples from 33 patients with stage IV non-small cell lung cancer enrolled in a clinical trial, MDSCs had the highest TET2 levels, which rose further after radiation and were most pronounced in patients whose cancer did not respond.View evidenceHide evidence

As stated33 patients

Why this verdict

The abstract supports only the general human association: TET2 expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy. It does not provide the sample size of 33, stage IV designation, blood-sample source, MDSC-specific ranking, post-radiation increase, or responder/nonresponder details. Those specifics may be in the full paper, but they are not verifiable from the supplied abstract-level profile.

1

Study evidence

TET2 expression correlates with poor clinical outcomes in advanced lung cancer patients receiving radiotherapy plus immunotherapy.

“We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy.”
Claim 2 of 5Not coveredIn mouse models of colon cancer, melanoma and lung cancer, myeloid-cell TET2 deletion was associated with slower tumor growth after radiation, longer survival and fewer, smaller lung metastases.View evidenceHide evidence

Why this verdict

The abstract supports the broad preclinical finding that myeloid-specific Tet2 deletion after radiotherapy suppresses tumor progression and metastasis. However, the supplied profile does not verify the specific cancer models named—colon cancer, melanoma, and lung cancer—nor longer survival, lung-metastasis location, or fewer/smaller metastases. Those details exceed the abstract-level evidence available here.

1

Study evidence

Myeloid-specific Tet2 deletion following radiotherapy suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting MDACs.

“Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses”
Claim 3 of 5SupportedResearchers at the University of Chicago identified a mechanism in which radiation therapy activates TET2 in bone-marrow immune cells, locking them into an immune-suppressing state that helps tumors resist treatment.View evidenceHide evidence

Why this verdict

At abstract depth, the paper supports the core claim that radiotherapy induces a TET2-driven immunosuppressive myeloid/MDSC program linked to treatment resistance/poor outcomes, and it reports a mechanistic p53–TET2 axis enforcing immunosuppressive chromatin states. The bone-marrow framing is broadly consistent with the abstract’s spatiotemporal mapping showing rapid initiation of the myeloid fate program in bone marrow, although the abstract does not provide detailed experimental support for every phrasing choice in the headline.

1

Study evidence

TET2 expression correlates with poor clinical outcomes in advanced lung cancer patients receiving radiotherapy plus immunotherapy.

“We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy.”
2

Study evidence

Spatiotemporal mapping shows the MDAC fate program initiates rapidly in the bone marrow after radiotherapy.

“spatiotemporal mapping shows that this fate program initiates rapidly in the bone marrow.”
Claim 4 of 5SupportedThe study says blocking TET2 made the same cells attack tumors instead, helping radiation and immunotherapy shrink tumors and control metastasis.View evidenceHide evidence

Why this verdict

The abstract supports a causal preclinical claim: myeloid-specific Tet2 deletion and pharmacologic TET2 inhibition redirect myeloid differentiation toward antigen-presenting MDACs, augment antitumor T-cell responses, improve radiotherapy responses, and help control primary and metastatic tumors with checkpoint blockade. The phrase that the cells 'attack tumors' is a simplified rendering; the abstract more specifically says the reprogrammed myeloid cells augment antitumor T-cell responses.

1

Study evidence

Myeloid-specific Tet2 deletion following radiotherapy suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting MDACs.

“Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses”
2

Study evidence

Pharmacologic TET2 inhibition recapitulated the Tet2 genetic-loss phenotype of redirecting myeloid differentiation toward antigen-presenting myeloid-derived activating cells (MDACs) and augmenting antitumor T cell responses (abstract).

“Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors.”
Claim 5 of 5SupportedThe story says an experimental TET2-blocking drug slowed tumor growth, reduced lung metastases when combined with radiation, and improved response to immunotherapy in mice.View evidenceHide evidence

Why this verdict

The abstract supports the core mouse/preclinical drug claim: pharmacologic TET2 inhibition recapitulates the Tet2-loss phenotype and, with radiotherapy and PD-L1 blockade, improves control of primary and metastatic tumors. The story’s framing as experimental and preclinical is appropriate. The abstract-level profile does not verify the lung-specific metastasis detail or quantitative magnitude, but the central therapeutic direction is supported.

1

Study evidence

Myeloid-specific Tet2 deletion following radiotherapy suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting MDACs.

“Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses”
2

Study evidence

Pharmacologic TET2 inhibition recapitulated the Tet2 genetic-loss phenotype of redirecting myeloid differentiation toward antigen-presenting myeloid-derived activating cells (MDACs) and augmenting antitumor T cell responses (abstract).

“Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors.”
Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

6 things the story did carry across
  • Radiotherapy induces a TET2-driven immunosuppressive myeloid/MDSC program that is clinically associated with poorer outcomes in advanced lung cancer patients receiving radio-immunotherapy.
  • The human clinical evidence is observational and correlational, not proof that TET2 causes worse outcomes in patients; potential confounding is not addressed in the abstract.
  • Myeloid-specific Tet2 deletion in mouse radiotherapy models causally redirects myeloid differentiation toward antigen-presenting MDACs, augments antitumor T-cell responses, suppresses primary tumor progression, and suppresses metastasis.
  • Pharmacologic TET2 inhibition in mouse tumor models recapitulates the genetic Tet2-loss phenotype and improves control of primary and metastatic tumors when combined with radiotherapy and PD-L1 checkpoint blockade.
  • Spatiotemporal mapping shows the relevant myeloid fate program initiates rapidly in the bone marrow after radiotherapy.
  • The preclinical mouse findings do not demonstrate clinical benefit in humans, and the abstract provides no quantitative effect sizes, sample sizes, dosing details, or statistical estimates for the animal and pharmacologic experiments.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalIn vivo, myeloid-specific Tet2 loss (and pharmacologic TET2 inhibition) reprograms myeloid differentiation toward antigen-presenting MDACs, improving radiotherapy responses and suppressing metastasis; combination with PD-L1 blockade is beneficial.In vivo mouse radiotherapy with myeloid-specific Tet2 deletionExpand

In plain English

In mouse tumor radiotherapy models, myeloid-lineage deletion of Tet2 after radiotherapy redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), suppresses primary tumor progression and metastasis, and augments antitumor T cell responses; pharmacologic TET2 inhibition phenocopies these effects and improves outcomes when combined with radiotherapy and PD-L1 blockade.

Key findings

  • Myeloid-specific Tet2 deletion following radiotherapy suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting MDACs.
  • Tet2 loss promotes generation of MDACs that augment antitumor T cell responses and is associated with enhanced CD8+ T cell cytotoxicity.
“Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2human in vivoRadiation induces a TET2-driven immunosuppressive myeloid program (MDSC) associated with poor outcomes in lung cancer patients receiving radio-immunotherapy.observational cohort study (human)Expand

In plain English

The abstract reports an observational association from advanced lung cancer patients treated with radiotherapy plus immunotherapy: TET2 is identified as a radiation-induced regulator of myeloid-derived suppressor cells, and higher TET2 expression correlates with poorer clinical outcomes in this patient group. Specific cohort, assay, and statistical details are not provided in the abstract.

Key findings

  • TET2 expression correlates with poor clinical outcomes in advanced lung cancer patients receiving radiotherapy plus immunotherapy.
“We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy.”
What this piece can’t prove
  • No information on the assay platform, normalization, or compartment (tumor vs. blood vs. sorted myeloid cells) used to measure TET2 expression.
  • Observational association may be subject to confounding and reverse causation; causality is not established from the reported correlation.

2 further details could not be confirmed from the summary.

3in vivo animalIn vivo, myeloid-specific Tet2 loss (and pharmacologic TET2 inhibition) reprograms myeloid differentiation toward antigen-presenting MDACs, improving radiotherapy responses and suppressing metastasis; combination with PD-L1 blockade is beneficial.in vivo pharmacologic combinationExpand

In plain English

In mouse tumor models, pharmacologic inhibition of TET2 recapitulated the myeloid reprogramming observed with myeloid-specific Tet2 loss (generation of antigen-presenting MDACs and augmented antitumor T cell responses) and, when combined with radiotherapy and anti–PD-L1 checkpoint blockade, improved control of primary tumors and suppressed metastatic disease (abstract-reported).

Key findings

  • Pharmacologic TET2 inhibition recapitulated the Tet2 genetic-loss phenotype of redirecting myeloid differentiation toward antigen-presenting myeloid-derived activating cells (MDACs) and augmenting antitumor T cell responses (abstract).
  • Pharmacologic TET2 inhibition, when combined with radiotherapy and anti–PD-L1 blockade, improved control of primary tumors and suppressed metastasis in mouse models (abstract).
“Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

4in vivo animalSpatiotemporal mapping shows MDAC fate programming initiates rapidly in the bone marrow after radiotherapy.in vivo time-course spatiotemporal mappingExpand

In plain English

The paper reports spatiotemporal mapping of myeloid fate after radiotherapy and states that the MDAC (myeloid-derived activating cell) fate program is initiated rapidly in the bone marrow following treatment. This mapping is presented as temporal and anatomical evidence locating the early initiation of the MDAC differentiation trajectory to the bone marrow compartment.

Key findings

  • Spatiotemporal mapping shows the MDAC fate program initiates rapidly in the bone marrow after radiotherapy.
“spatiotemporal mapping shows that this fate program initiates rapidly in the bone marrow.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

5otherMechanism: a radiation-responsive p53–TET2 axis reduces m5C on chromatin-associated RNAs, promoting immunosuppressive chromatin compaction and interferon-signal silencing; Tet2 loss restores accessibility and enhances CD8+ T cell cytotoxicity.Expand

In plain English

Abstract-level mechanistic claim: following radiotherapy a radiation-responsive p53–TET2 axis reduces 5-methylcytosine (m5C) on chromatin-associated RNAs (caRNAs), which is reported to promote immunosuppressive chromatin compaction and silencing of interferon signaling; loss or inhibition of Tet2 is reported to restore chromatin accessibility and enhance CD8+ T cell cytotoxicity.

Key findings

  • A radiation-responsive p53–TET2 axis decreases m5C on chromatin-associated RNAs, which is reported to drive immunosuppressive chromatin compaction and silencing of interferon signaling; Tet2 loss restores chromatin accessibility and enhances CD8+ T cell cytotoxicity.
“Mechanistically, a radiation-responsive p53-TET2 axis decreases m5C on chromatin-associated RNAs (caRNAs), enforcing immunosuppressive chromatin compaction and silencing interferon signaling, whereas Tet2 loss restores chromatin accessibility and enhances CD8+ T cell cytotoxicity.”
What this piece can’t prove
  • Abstract does not specify the exact assays or experimental models used to measure caRNA m5C, chromatin compaction/accessibility, interferon signaling, or CD8+ T cell cytotoxicity.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

Candidate

Author response for "Actin-Dependent Regulation of RSV F-Mediated Cell-cell Fusion Revealed by Visualizing Its Spatiotemporal Dynamics"

2026 · Crossref

Source (opens in a new tab)
CandidateOpen access

Decoding Treatment Response and Prognosis in Unresectable Locally Advanced Non-Small Cell Lung Cancer by Integrating Spatiotemporal Heterogeneity From 18F-FDG Positron Emission Tomography-Computed Tomography: A Multicenter Study.

2026 · Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Author response: SETDB1 enables development beyond cleavage stages by extinguishing the MERVL-driven two-cell totipotency transcriptional program in the mouse embryo

2026 · Crossref

Source (opens in a new tab)
Candidate

Author response: Maternal SETDB1 enables development beyond cleavage stages by extinguishing the MERVL-driven 2-cell totipotency transcriptional program in the mouse embryo

2026 · Crossref

Source (opens in a new tab)

And 32 more candidates considered.